ATH Price sensitive 5 May 2025, 8:53 AM

Alterity Granted U.S. FDA Fast Track Designation for ATH434

Alterity Therapeutics Ltd

Sign in to open PDF

No summary is available for this announcement — sign in to read the PDF in full.

Sign in for more about this company, including guidance changes and other insights.
Sign in